EUCTR2012-003111-58-DE进行中（未招募）1 期
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects - TOMMORROW
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 3,494
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or postmenopausal female subject between 65 and 83 years of age, inclusive at the time of the screening visit.
- •2. The subject must be cognitively normal at baseline, scoring as indicated for the following tests:
- •- Clinical Dementia Rating (CDR)=0.
- •- At least one memory test above -1.5 SD of the demographically corrected normative mean.
- •3. The subject must score =25 on the Mini Mental Status Examination (MMSE) at the screening visit after the education and age adjustment referenced in Appendix G of the protocol.
- •4. All subjects require a project partner who can separately complete an Acknowledgment Form on his/her own behalf and take part in the study to provide information on the cognitive, functional, and behavioral status of the subject and to assist with monitoring of study medication, if needed.
- •5. The subject has the ability and intention to participate in regular study visits, in the opinion of the Investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3500
排除标准
- •1. The subject has a current diagnosis or history of any type of cognitive impairment or dementia, or has a current diagnosis or history of neurological/psychiatric disorder or any other diagnosis that significantly affects cognitive performance (eg, mental retardation, organic mental disorder).
- •2. The subject has a current diagnosis of significant psychiatric illness, per the Diagnostic & Statistical Manual of Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) (including but not limited to major depressive disorder, anxiety disorders) and is in an acute phase/episode, or the subject has a current diagnosis or history of schizophrenia or bipolar disorder.
- •3. The subject has glycosylated hemoglobin (HbA1c) >8.0% at the time of baseline or requires treatment with insulin, triple oral antidiabetic therapy or a peroxisome proliferator-activated receptor-gamma agonist.
- •The subject should be on a stable antidiabetic regimen for at least 3 months prior to enrollment.
- •4. The subject has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance. History of HIV infection is considered exclusionary for this study.
- •5.The subject has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse/dependence within 2 years prior to the Screening Visit.
- •6.The subject has a history or current diagnosis of macular edema or macular degeneration.
- •7. If female, the subject has a history of postmenopausal fractures with no or minimal trauma (eg, wrist, hip, lumbar or thoracic vertebral fracture).
- •8. The subject has a history or current diagnosis of congestive heart failure (CHF), New York Heart Association Class III-IV.
- •9. The subject has been exposed to cognitive tests performed in this study within 6 months prior to the Screening Visit with the exception of the MMSE.
- •10. The subject’s TOMM40 rs10524523 or APOE genotypes or APOE phenotype are known by the subject or the study staff participating in this study.
研究者
相似试验
进行中（未招募）
不适用
A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients with Mild to Moderate Essential Hypertension.Mild to moderate essential hypertensionMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionEUCTR2007-007516-28-DECytos Biotechnology AG80
进行中（未招募）
1 期
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying its OnsetMild cognitive impairment due to Alzheimer’s diseaseMedDRA version: 18.1 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 100000004852EUCTR2012-003111-58-GBTakeda Development Centre Europe Ltd3,494
进行中（未招募）
不适用
A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients with Mild to Moderate Essential Hypertension.EUCTR2007-005843-93-DECytos Biotechnology AG60
进行中（未招募）
不适用
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying its OnsetEUCTR2012-003111-58-ITTakeda Development Centre Europe Ltd5,800
已完成
4 期
A study for Evaluation of effectiveness and Safety of Minoxidil (5%) plus Finasteride (0.1%) Solution in Adult Male Patients with Androgenetic AlopeciaCTRI/2016/03/006724Intas Pharmaceuticals Ltd160